Literature DB >> 9679715

Intracoronary stenting and risk for major adverse cardiac events during the first month.

H Schühlen1, A Kastrati, J Dirschinger, J Hausleiter, S Elezi, A Wehinger, J Pache, M Hadamitzky, A Schömig.   

Abstract

BACKGROUND: Our rationale for this study was to analyze the risk for procedural failure of attempted stenting and the risk for major adverse cardiac events (MACE) after success and to develop a risk stratification protocol for successful procedures. METHODS AND
RESULTS: Stenting was attempted in 2894 procedures during the 5-year study period (success in 98.3% of 3815 lesions). After failure, the MACE rate was 42.6%. The risk for failure was higher for lesions in the left circumflex coronary artery or in venous bypass grafts and after an acute occlusion before stenting; it increased with stenosis length or grade and decreased with vessel size and growing institutional experience in stenting. After success, death occurred in 0.8%, death or myocardial infarction in 2.0%, and any MACE in 3.6%. Independent risk factors for MACE were older age, diabetes, acute myocardial infarction, unstable angina, impaired left ventricular function, residual dissections, stent overlap, longer stented segments, and a postprocedural regimen without ticlopidine. Procedural factors were substantially stronger predictors than operator-independent variables available before procedures. Overall, the risk declined after the first 3 days. Two major factors exhibited time-dependent variations of their influence: while residual dissections were the dominant risk factor within the first 3 days with a reduction after that, no protective effect of ticlopidine could be identified before day 3. From these results, we derived a risk stratification protocol for individual procedures.
CONCLUSIONS: These results underscore the importance of optimal angiographic results and the need for antiplatelet regimens with immediate onset. Our risk stratification protocol may guide individual postprocedural care and allow us to compare risk profiles of different study populations and to devise quality control programs for stenting.

Entities:  

Mesh:

Year:  1998        PMID: 9679715     DOI: 10.1161/01.cir.98.2.104

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting.

Authors:  S R Steinhubl; E J Topol
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 2.  Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.

Authors:  P A McCullough; K R Marks
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

3.  Sirolimus-eluting stents for percutaneous coronary intervention in acute myocardial infarction Lesson from a case-controlled comparison of bare metal versus drug-eluting stents in thrombus-laden lesions.

Authors:  F Weber; H Schneider; C Schwarz; C Holzhausen; M Petzsch; C A Nienaber
Journal:  Z Kardiol       Date:  2004-12

4.  Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial.

Authors:  Igor Mrdovic; Lidija Savic; Ratko Lasica; Gordana Krljanac; Milika Asanin; Natasa Brdar; Nemanja Djuricic; Natasa Cvetinovic; Jelena Marinkovic; Jovan Perunicic
Journal:  Heart Vessels       Date:  2012-09-14       Impact factor: 2.037

5.  Clinical outcomes in diabetic and non-diabetic patients with drug-eluting stents: results from the first phase of the prospective multicenter German DES.DE registry.

Authors:  Ibrahim Akin; Alexander Bufe; Steffen Schneider; Holger Reinecke; Lars Eckardt; Gert Richardt; Detlev Burska; Jochen Senges; Karl-Heinz Kuck; Christoph A Nienaber
Journal:  Clin Res Cardiol       Date:  2010-03-11       Impact factor: 5.460

Review 6.  Clopidogrel and coronary stenting: what is the next question?

Authors:  S A Moore; S R Steinhubl
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

7.  In-hospital complications after invasive strategy for the management of Non STEMI: women fare as well as men.

Authors:  Caroline Berthillot; Dominique Stephan; Michel Chauvin; Gerald Roul
Journal:  BMC Cardiovasc Disord       Date:  2010-06-24       Impact factor: 2.298

8.  Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.

Authors:  John S Douglas; William S Weintraub; David Holmes
Journal:  Clin Cardiol       Date:  2003-10       Impact factor: 2.882

9.  Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.

Authors:  Tuba Bilsel; Tamer Akbulut; Kemal Yesilcimen; Sait Terzi; Nurten Sayar; Sennur Unal Dayi; Haldun Akgoz; Mehmet Ergelen; Figen Ciloglu
Journal:  Heart Vessels       Date:  2006-03       Impact factor: 2.037

10.  Predictors of long-term survival in acute coronary syndrome patients with left ventricular dysfunction after percutaneous coronary intervention.

Authors:  Doo Hwan Lee; Myung Ho Jeong; Jung Ae Rhee; Jin Su Choi; Ki Hong Lee; Min Goo Lee; Doo Sun Sim; Keun-Ho Park; Nam Sik Yoon; Hyun Ju Yoon; Kye Hun Kim; Hyung Wook Park; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  Korean Circ J       Date:  2012-10-31       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.